CANBRIDGE-B (01228) Announces Monthly Return as of 28 February 2026

Bulletin Express03-05

CANbridge Pharmaceuticals Inc. reported that its authorized share capital remained unchanged at 5,000,000,000 ordinary shares, with a par value of USD 0.00001 each, amounting to USD 50,000 as of 28 February 2026. The number of issued shares rose from 511.22 million (exactly 511,222,234) to 511.25 million (511,252,234), representing an increase of 30,000 shares during the month.

According to the announcement, 30,000 new shares were issued under the Post-IPO Share Option Scheme, with HKD 80,400 in total funds raised from option exercises. After these exercises and the lapse of 679,875 options, 13,967,700 share options remained outstanding under the scheme. The Pre-IPO Equity Incentive Plan continued to have 21,131,360 shares available for issuance, while the Post-IPO RSU Scheme had no newly issued or transferred shares during the month.

The announcement confirmed that the public float requirement remained in compliance at the close of the reporting period. The total authorized share capital stood at USD 50,000, with no changes from the preceding month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157599892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157599892","market":"us","top_or_hot":-1,"title":"CANBRIDGE-B (01228) Announces Monthly Return as of 28 February 2026","media":"Bulletin Express","content":"<p>CANbridge Pharmaceuticals Inc. reported that its authorized share capital remained unchanged at 5,000,000,000 ordinary shares, with a par value of USD 0.00001 each, amounting to USD 50,000 as of 28 February 2026. The number of issued shares rose from 511.22 million (exactly 511,222,234) to 511.25 million (511,252,234), representing an increase of 30,000 shares during the month.</p>\n<p>According to the announcement, 30,000 new shares were issued under the Post-IPO Share Option Scheme, with HKD 80,400 in total funds raised from option exercises. After these exercises and the lapse of 679,875 options, 13,967,700 share options remained outstanding under the scheme. The Pre-IPO Equity Incentive Plan continued to have 21,131,360 shares available for issuance, while the Post-IPO RSU Scheme had no newly issued or transferred shares during the month.</p>\n<p>The announcement confirmed that the public float requirement remained in compliance at the close of the reporting period. The total authorized share capital stood at USD 50,000, with no changes from the preceding month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANBRIDGE-B (01228) Announces Monthly Return as of 28 February 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANBRIDGE-B (01228) Announces Monthly Return as of 28 February 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-05 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANbridge Pharmaceuticals Inc. reported that its authorized share capital remained unchanged at 5,000,000,000 ordinary shares, with a par value of USD 0.00001 each, amounting to USD 50,000 as of 28 February 2026. The number of issued shares rose from 511.22 million (exactly 511,222,234) to 511.25 million (511,252,234), representing an increase of 30,000 shares during the month.</p>\n<p>According to the announcement, 30,000 new shares were issued under the Post-IPO Share Option Scheme, with HKD 80,400 in total funds raised from option exercises. After these exercises and the lapse of 679,875 options, 13,967,700 share options remained outstanding under the scheme. The Pre-IPO Equity Incentive Plan continued to have 21,131,360 shares available for issuance, while the Post-IPO RSU Scheme had no newly issued or transferred shares during the month.</p>\n<p>The announcement confirmed that the public float requirement remained in compliance at the close of the reporting period. The total authorized share capital stood at USD 50,000, with no changes from the preceding month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01228","symbol_name":"北海康成-B","start_time":0,"source_url":"","article_id":"1157599892","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157599892","pubTimestamp":1772703413,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CANbridge Pharmaceuticals Inc. reported that its authorized share capital remained unchanged at 5,000,000,000 ordinary shares, with a par value of USD 0.00001 each, amounting to USD 50,000 as of 28...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01228":"北海康成-B"},"translate_title":"康桥-B(01228)公布截至2026年2月28日止月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":1},"content_text":"CANbridge Pharmaceuticals Inc. reported that its authorized share capital remained unchanged at 5,000,000,000 ordinary shares, with a par value of USD 0.00001 each, amounting to USD 50,000 as of 28 February 2026. The number of issued shares rose from 511.22 million (exactly 511,222,234) to 511.25 million (511,252,234), representing an increase of 30,000 shares during the month.\nAccording to the announcement, 30,000 new shares were issued under the Post-IPO Share Option Scheme, with HKD 80,400 in total funds raised from option exercises. After these exercises and the lapse of 679,875 options, 13,967,700 share options remained outstanding under the scheme. The Pre-IPO Equity Incentive Plan continued to have 21,131,360 shares available for issuance, while the Post-IPO RSU Scheme had no newly issued or transferred shares during the month.\nThe announcement confirmed that the public float requirement remained in compliance at the close of the reporting period. The total authorized share capital stood at USD 50,000, with no changes from the preceding month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157599892","isCrawlerRequest":true}